|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: CCDC190 |
Gene summary for CCDC190 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | CCDC190 | Gene ID | 339512 |
| Gene name | coiled-coil domain containing 190 | |
| Gene Alias | C1orf110 | |
| Cytomap | 1q23.3 | |
| Gene Type | protein-coding | GO ID | NA | UniProtAcc | Q86UF4 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 339512 | CCDC190 | CCI_1 | Human | Cervix | CC | 2.30e-07 | 5.00e-01 | 0.528 |
| 339512 | CCDC190 | CCI_2 | Human | Cervix | CC | 2.86e-05 | 3.35e-01 | 0.5249 |
| 339512 | CCDC190 | LZE2D | Human | Esophagus | HGIN | 6.44e-06 | 5.85e-01 | 0.0642 |
| 339512 | CCDC190 | LZE2T | Human | Esophagus | ESCC | 1.80e-11 | 1.00e+00 | 0.082 |
| 339512 | CCDC190 | LZE7T | Human | Esophagus | ESCC | 2.07e-09 | 6.19e-01 | 0.0667 |
| 339512 | CCDC190 | LZE8T | Human | Esophagus | ESCC | 9.33e-11 | 3.37e-01 | 0.067 |
| 339512 | CCDC190 | LZE20T | Human | Esophagus | ESCC | 1.30e-10 | 4.18e-01 | 0.0662 |
| 339512 | CCDC190 | LZE21D1 | Human | Esophagus | HGIN | 4.41e-04 | 4.25e-01 | 0.0632 |
| 339512 | CCDC190 | LZE22D1 | Human | Esophagus | HGIN | 3.52e-12 | 7.02e-01 | 0.0595 |
| 339512 | CCDC190 | LZE22T | Human | Esophagus | ESCC | 6.95e-12 | 8.56e-01 | 0.068 |
| 339512 | CCDC190 | LZE24T | Human | Esophagus | ESCC | 3.10e-46 | 1.39e+00 | 0.0596 |
| 339512 | CCDC190 | LZE21T | Human | Esophagus | ESCC | 2.27e-11 | 6.39e-01 | 0.0655 |
| 339512 | CCDC190 | P1T-E | Human | Esophagus | ESCC | 3.58e-07 | 2.95e-01 | 0.0875 |
| 339512 | CCDC190 | P4T-E | Human | Esophagus | ESCC | 2.81e-13 | 3.34e-01 | 0.1323 |
| 339512 | CCDC190 | P9T-E | Human | Esophagus | ESCC | 4.09e-44 | 1.07e+00 | 0.1131 |
| 339512 | CCDC190 | P15T-E | Human | Esophagus | ESCC | 1.05e-10 | 3.26e-01 | 0.1149 |
| 339512 | CCDC190 | P20T-E | Human | Esophagus | ESCC | 2.54e-64 | 1.40e+00 | 0.1124 |
| 339512 | CCDC190 | P22T-E | Human | Esophagus | ESCC | 6.62e-20 | 3.89e-01 | 0.1236 |
| 339512 | CCDC190 | P23T-E | Human | Esophagus | ESCC | 3.47e-64 | 1.70e+00 | 0.108 |
| 339512 | CCDC190 | P27T-E | Human | Esophagus | ESCC | 1.13e-16 | 3.35e-01 | 0.1055 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| CCDC190 | insertion | Frame_Shift_Ins | novel | c.254_255insCAAATGCATAGCAGACTCTATCAAA | p.Leu86LysfsTer25 | p.L86Kfs*25 | Q86UF4 | protein_coding | TCGA-BH-A0HK-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | ||
| CCDC190 | SNV | Missense_Mutation | c.825N>C | p.Glu275Asp | p.E275D | Q86UF4 | protein_coding | deleterious(0) | probably_damaging(0.963) | TCGA-C5-A1MH-01 | Cervix | cervical & endocervical cancer | Female | >=65 | III/IV | Chemotherapy | cisplatin | PD | |
| CCDC190 | SNV | Missense_Mutation | c.328C>T | p.Arg110Cys | p.R110C | Q86UF4 | protein_coding | deleterious(0.02) | benign(0.241) | TCGA-MA-AA42-01 | Cervix | cervical & endocervical cancer | Female | >=65 | I/II | Unknown | Unknown | SD | |
| CCDC190 | SNV | Missense_Mutation | novel | c.73G>A | p.Glu25Lys | p.E25K | Q86UF4 | protein_coding | deleterious(0.01) | possibly_damaging(0.694) | TCGA-VS-A8QF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| CCDC190 | SNV | Missense_Mutation | c.455A>C | p.Lys152Thr | p.K152T | Q86UF4 | protein_coding | tolerated(0.07) | benign(0.08) | TCGA-A6-2682-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Chemotherapy | 5 | PD | |
| CCDC190 | SNV | Missense_Mutation | c.845N>T | p.Ser282Phe | p.S282F | Q86UF4 | protein_coding | tolerated(0.08) | benign(0.035) | TCGA-CA-6717-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Chemotherapy | oxaliplatin | CR | |
| CCDC190 | SNV | Missense_Mutation | c.210C>A | p.Phe70Leu | p.F70L | Q86UF4 | protein_coding | tolerated(0.59) | benign(0.009) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| CCDC190 | SNV | Missense_Mutation | novel | c.477N>T | p.Glu159Asp | p.E159D | Q86UF4 | protein_coding | deleterious(0.02) | possibly_damaging(0.655) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CCDC190 | SNV | Missense_Mutation | novel | c.205N>G | p.Lys69Glu | p.K69E | Q86UF4 | protein_coding | deleterious(0.01) | benign(0.187) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| CCDC190 | SNV | Missense_Mutation | novel | c.43N>T | p.Asp15Tyr | p.D15Y | Q86UF4 | protein_coding | deleterious(0) | probably_damaging(0.992) | TCGA-A5-A2K5-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |